Literature DB >> 35869339

Cardiovascular health and mortality in Cushing's disease.

Amy Coulden1,2,3, Ross Hamblin1,2,3, John Wass4, Niki Karavitaki5,6,7.   

Abstract

Exposure to cortisol excess in Cushing's disease (CD) results in increased cardiovascular morbidity and reduces survival, with cardiovascular disease being a leading cause of death. At diagnosis, a significant number of patients have adverse cardiovascular profiles (e.g., obesity, diabetes or impaired glucose tolerance, dyslipidemia, hypertension, cardiac abnormalities and vascular disease). Remission of hypercortisolemia reduces but does not completely eliminate the cardiovascular complications; hazard ratios for myocardial infarction and stroke are high during long-term monitoring, highlighting the long-lasting effects of hypercortisolism and the importance of the timely diagnosis and successful management of this condition. Data on mortality of patients in remission are not consistent but in a multicenter study, an increased all-cause and circulatory mortality in patients with CD in remission for at least 10 years has been demonstrated. Cardiovascular morbidity requires particular focus and effective management during the care of patients with CD, from their presentation until long-term follow up.
© 2022. Crown.

Entities:  

Keywords:  Cardiovascular Health; Cushing’s Disease; Hypercortisolemia; Mortality

Year:  2022        PMID: 35869339     DOI: 10.1007/s11102-022-01258-4

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   3.599


  17 in total

1.  Outcome of Cushing's disease following transsphenoidal surgery in a single center over 20 years.

Authors:  Zaki K Hassan-Smith; Mark Sherlock; Raoul C Reulen; Wiebke Arlt; John Ayuk; Andrew A Toogood; Mark S Cooper; Alan P Johnson; Paul M Stewart
Journal:  J Clin Endocrinol Metab       Date:  2012-01-25       Impact factor: 5.958

2.  Mortality in Cushing's syndrome: systematic analysis of a large series with prolonged follow-up.

Authors:  G Ntali; A Asimakopoulou; T Siamatras; J Komninos; D Vassiliadi; M Tzanela; S Tsagarakis; A B Grossman; J A H Wass; N Karavitaki
Journal:  Eur J Endocrinol       Date:  2013-10-08       Impact factor: 6.664

3.  Overall and Disease-Specific Mortality in Patients With Cushing Disease: A Swedish Nationwide Study.

Authors:  Oskar Ragnarsson; Daniel S Olsson; Eleni Papakokkinou; Dimitrios Chantzichristos; Per Dahlqvist; Elin Segerstedt; Tommy Olsson; Maria Petersson; Katarina Berinder; Sophie Bensing; Charlotte Höybye; Britt Edén-Engström; Pia Burman; Lorenza Bonelli; Cecilia Follin; David Petranek; Eva Marie Erfurth; Jeanette Wahlberg; Bertil Ekman; Anna-Karin Åkerman; Erik Schwarcz; Ing-Liss Bryngelsson; Gudmundur Johannsson
Journal:  J Clin Endocrinol Metab       Date:  2019-06-01       Impact factor: 5.958

4.  Clinical relevance of cardiac structure and function abnormalities in patients with Cushing's syndrome before and after cure.

Authors:  Paola M Toja; Giovanna Branzi; Francesca Ciambellotti; Piero Radaelli; Martina De Martin; Laura Maria Lonati; Massimo Scacchi; Gianfranco Parati; Francesco Cavagnini; Francesca Pecori Giraldi
Journal:  Clin Endocrinol (Oxf)       Date:  2012-03       Impact factor: 3.478

5.  Body composition and cardiovascular risk markers after remission of Cushing's disease: a prospective study using whole-body MRI.

Authors:  Eliza B Geer; Wei Shen; Erika Strohmayer; Kalmon D Post; Pamela U Freda
Journal:  J Clin Endocrinol Metab       Date:  2012-03-14       Impact factor: 5.958

Review 6.  Epidemiology and mortality of Cushing's syndrome.

Authors:  Osamah A Hakami; Shahzada Ahmed; Niki Karavitaki
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2021-03-15       Impact factor: 4.690

7.  MRI assessment of lean and adipose tissue distribution in female patients with Cushing's disease.

Authors:  Eliza B Geer; Wei Shen; Dympna Gallagher; Mark Punyanitya; Helen C Looker; Kalmon D Post; Pamela U Freda
Journal:  Clin Endocrinol (Oxf)       Date:  2010-10       Impact factor: 3.478

8.  Metabolic and cardiovascular outcomes in patients with Cushing's syndrome of different aetiologies during active disease and 1 year after remission.

Authors:  Roberta Giordano; Andreea Picu; Elisa Marinazzo; Valentina D'Angelo; Rita Berardelli; Ioannis Karamouzis; Daniela Forno; Domenico Zinnà; Mauro Maccario; Ezio Ghigo; Emanuela Arvat
Journal:  Clin Endocrinol (Oxf)       Date:  2011-09       Impact factor: 3.478

Review 9.  Consensus on diagnosis and management of Cushing's disease: a guideline update.

Authors:  Maria Fleseriu; Richard Auchus; Irina Bancos; Anat Ben-Shlomo; Jerome Bertherat; Nienke R Biermasz; Cesar L Boguszewski; Marcello D Bronstein; Michael Buchfelder; John D Carmichael; Felipe F Casanueva; Frederic Castinetti; Philippe Chanson; James Findling; Mônica Gadelha; Eliza B Geer; Andrea Giustina; Ashley Grossman; Mark Gurnell; Ken Ho; Adriana G Ioachimescu; Ursula B Kaiser; Niki Karavitaki; Laurence Katznelson; Daniel F Kelly; André Lacroix; Ann McCormack; Shlomo Melmed; Mark Molitch; Pietro Mortini; John Newell-Price; Lynnette Nieman; Alberto M Pereira; Stephan Petersenn; Rosario Pivonello; Hershel Raff; Martin Reincke; Roberto Salvatori; Carla Scaroni; Ilan Shimon; Constantine A Stratakis; Brooke Swearingen; Antoine Tabarin; Yutaka Takahashi; Marily Theodoropoulou; Stylianos Tsagarakis; Elena Valassi; Elena V Varlamov; Greisa Vila; John Wass; Susan M Webb; Maria C Zatelli; Beverly M K Biller
Journal:  Lancet Diabetes Endocrinol       Date:  2021-10-20       Impact factor: 32.069

10.  Multisystem morbidity and mortality in Cushing's syndrome: a cohort study.

Authors:  Olaf M Dekkers; Erzsébet Horváth-Puhó; Jens Otto L Jørgensen; Suzanne C Cannegieter; Vera Ehrenstein; Jan P Vandenbroucke; Alberto M Pereira; Henrik Toft Sørensen
Journal:  J Clin Endocrinol Metab       Date:  2013-03-26       Impact factor: 5.958

View more
  1 in total

1.  Special issue: Cushing's disease update.

Authors:  Maria Fleseriu
Journal:  Pituitary       Date:  2022-08-24       Impact factor: 3.599

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.